Inhibition of Feline leukemia virus replication by the integrase inhibitor Raltegravir

Veterinary Microbiology

Volumn 152, Issue 1-2, 2011, Pages 165-168

  Cattori, Valentino ^a   Weibel, Beatrice ^a   Lutz, Hans ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Antiretroviral therapy; Feline leukemia virus; Integrase inhibitor; Progressive infection; Raltegravir; Retrovirus

Indexed keywords

RALTEGRAVIR;

ANIMAL CELL; ARTICLE; CELL LINE; DRUG EFFICACY; EMBRYO; FELINE LEUKEMIA; FELINE LEUKEMIA VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; NONHUMAN; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; APOPTOSIS; CATS; CELL LINE; CELL SURVIVAL; INTEGRASE INHIBITORS; LEUKEMIA VIRUS, FELINE; MICROBIAL SENSITIVITY TESTS; PYRROLIDINONES; VIRUS REPLICATION;

ANIMALIA; FELIDAE; FELINE LEUKEMIA VIRUS; FELIS CATUS; GAMMARETROVIRUS; XENOTROPIC MURINE LEUKEMIA VIRUS;

EID: 79960413042     PISSN: 03781135     EISSN: 18732542     Source Type: Journal    
DOI: 10.1016/j.vetmic.2011.03.039     Document Type: Article

References (28)

1. Akhtardanesh B., Ziaali N., Sharifi H., Rezaei S. Feline immunodeficiency virus, feline leukemia virus and Toxoplasma gondii in stray and household cats in Kerman-Iran: seroprevalence and correlation with clinical and laboratory findings. Res. Vet. Sci. 2010, 89:306-310.
2. Bar-Magen T., Sloan R.D., Donahue D.A., Kuhl B.D., Zabeida A., Xu H., Oliveira M., Hazuda D.J., Wainberg M.A. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J. Virol. 2010, 84:9210-9216.
3. Blanco K., Prendas J., Cortes R., Jimenez C., Dolz G. Seroprevalence of viral infections in domestic cats in Costa Rica. J. Vet. Med. Sci. 2009, 71:661-663.
4. Charpentier C., Larrouy L., Collin G., Damond F., Matheron S., Chene G., Nie T., Schinazi R., Brun-Vezinet F., Descamps D. In vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572. Aids 2010, 4:4.
5. de Mari K., Maynard L., Sanquer A., Lebreux B., Eun H.M. Therapeutic effects of recombinant feline interferon-omega on feline leukemia virus (FeLV)-infected and FeLV/feline immunodeficiency virus (FIV)-coinfected symptomatic cats. J. Vet. Intern. Med. 2004, 18:477-482.
6. Duarte A., Castro I., Pereira da Fonseca I.M., Almeida V., Madeira de Carvalho L.M., Meireles J., Fazendeiro M.I., Tavares L., Vaz Y. Survey of infectious and parasitic diseases in stray cats at the Lisbon Metropolitan Area, Portugal. J. Feline Med. Surg. 2010, 12:441-446.
7. Gleich S.E., Krieger S., Hartmann K. Prevalence of feline immunodeficiency virus and feline leukaemia virus among client-owned cats and risk factors for infection in Germany. J. Feline Med. Surg. 2009, 11:985-992.
8. Gomes-Keller M.A., Gönczi E., Grenacher B., Tandon R., Hofman-Lehmann R., Lutz H. Fecal shedding of infectious feline leukemia virus and its nucleic acids: a transmission potential. Vet. Microbiol. 2009, 134:208-217.
9. Hartmann K., Donath A., Beer B., Egberink H.F., Horzinek M.C., Lutz H., Hoffmann-Fezer G., Thum I., Thefeld S. Use of two virustatica (AZT PMEA) in the treatment of FIV and of FeLV seropositive cats with clinical symptoms. Vet. Immunol. Immunopathol. 1992, 35:167-175.
10. Hocqueloux L., Prazuck T., Avettand-Fenoel V.r., Lafeuillade A., Cardon B., Viard J.-P., Rouzioux C. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. Aids 2010, 24. 1598-1601 1510.1097/QAD, 1590b1013e32833b32861ba.
11. Hofmann-Lehmann R., Cattori V., Tandon R., Boretti F.S., Meli M.L., Riond B., Lutz H. How molecular methods change our views of FeLV infection and vaccination. Vet. Immunol. Immunopathol. 2008, 123:119-123.
12. Kassahun K., McIntosh I., Cui D., Hreniuk D., Merschman S., Lasseter K., Azrolan N., Iwamoto M., Wagner J.A., Wenning L.A. Metabolism and disposition in humans of Raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab. Dispos. 2007, 35:1657-1663.
13. Koh Y., Matreyek K.A., Engelman A. Differential sensitivities of retroviruses to integrase strand transfer inhibitors. J. Virol. 2011, 85:3677-3682.
14. Le G., Vandegraaff N., Rhodes D.I., Jones E.D., Coates J.A.V., Lu L., Li X., Yu C., Feng X., Deadman J.J. Discovery of potent HIV integrase inhibitors active against Raltegravir resistant viruses. Bioorg. Med. Chem. Lett. 2010, 20:5013-5018.
15. Lutz H., Addie D., Belák S., Boucraut-Baralon C., Egberink H., Frymus T., Gruffydd-Jones T., Hartmann K., Hosie M.J., Lloret A., Marsilio F., Pennisi M.G., Radford A.D., Thiry E., Truyen U., Horzinek M.C. Feline leukaemia ABCD guidelines on prevention and management. J. Feline Med. Surg. 2009, 11:565-574.
16. Lutz H., Pedersen N., Higgins J., Hubscher U., Troy F.A., Theilen G.H. Humoral immune reactivity to feline leukemia virus and associated antigens in cats naturally infected with feline leukemia virus. Cancer Res. 1980, 40:3642-3651.
17. Meli M.L., Cattori V., Martinez F., Lopez G., Vargas A., Simon M.A., Zorrilla I., Munoz A., Palomares F., Lopez-Bao J.V., Pastor J., Tandon R., Willi B., Hofmann-Lehmann R., Lutz H. Feline leukemia virus and other pathogens as important threats to the survival of the critically endangered Iberian lynx (Lynx pardinus). PLoS One 2009, 4:e4744.
18. Min S., Song I., Borland J., Chen S., Lou Y., Fujiwara T., Piscitelli S.C. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob. Agents Chemother. 2010, 54:254-258.
19. Office of AIDS Research Advisory Council (OARAC) et al., 2009. Panel on Antiretroviral Guidelines for Adults and Adolescents, Services, U.D.o.H.a.H., 2009, Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents, pp. 1-161. http://www.aidsinfo.nih.gov/.
20. Paprotka T., Venkatachari N.J., Chaipan C., Burdick R., Delviks-Frankenberry K.A., Hu W.-S., Pathak V.K. Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs. J. Virol. 2010, 84:5719-5729.
21. Prada N., Markowitz M. Novel integrase inhibitors for HIV. Expert Opin. Investig. Drugs 2010, 19:1087-1098.
22. Serrao E., Odde S., Ramkumar K., Neamati N. Raltegravir, elvitegravir, and metoogravir: the birth of " me-too" HIV-1 integrase inhibitors. Retrovirology 2009, 6:25.
23. Shimura K., Kodama E., Sakagami Y., Matsuzaki Y., Watanabe W., Yamataka K., Watanabe Y., Ohata Y., Doi S., Sato M., Kano M., Ikeda S., Matsuoka M. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J. Virol. 2008, 82:764-774.
24. Singh I.R., Gorzynski J.E., Drobysheva D., Bassit L., Schinazi R.F. Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome. PLoS One 2010, 5:e9948.
25. Smith R., Gottlieb G., Miller A.D. Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors. Retrovirology 2010, 7:70.
26. Song I., Min S.S., Borland J., Lou Y., Chen S., Ishibashi T., Wajima T., Piscitelli S.C. Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects. J. Acquir. Immune Defic. Syndr. 2010, 2010:25.
27. ® real-time polymerase chain reaction. J. Virol. Methods 2005, 130:124-132.
28. Ter Heine R., Mulder J.W., van Gorp E.C., Wagenaar J.F., Beijnen J.H., Huitema A.D. Intracellular and plasma steady-state pharmacokinetics of Raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients. Br. J. Clin. Pharmacol. 2010, 69:475-483.